Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …

Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

Converting checkpoint inhibitor (CPI)-resistant individuals to being responsive requires
identifying suppressive mechanisms. We identify TREM2+ tumor-associated macrophages …

The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional
T cells are characterized by reduced proliferative capacity, decreased effector function, and …

Immunotherapy has revolutionized cancer therapy, largely attributed to the success of
immune-checkpoint blockade. However, there are subsets of patients across multiple …

Objective Programmed cell death protein 1 (PD-1) checkpoint inhibition and adoptive
cellular therapy have had limited success in patients with microsatellite stable colorectal …